{"answer":{"query":"anoro ellipta","resolved_as":"name","packages":3,"applications":["NDA203975"],"identity":{"application_numbers":["NDA203975"],"marketing_categories":["NDA","NDA AUTHORIZED GENERIC"],"labelers":[{"text":"GLAXOSMITHKLINE","untrusted":true},{"text":"PRASCO LABORATORIES","untrusted":true}],"dosage_forms":[{"text":"POWDER","untrusted":true}],"marketing_start":{"earliest":"2014-01-31","latest":"2025-04-11","packages_with_a_start_date":3}},"price":{"median_negotiated_over_nadac":null,"packages_compared":0,"packages_listed":3,"negotiated_price_ends":null,"rows":[{"ndc":"00173086906","name":{"text":"ANORO ELLIPTA 62.5/25 MCGINH PWDR 1X7 DS INST","untrusted":true},"class":"B","nadac_per_unit":8.03278,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00173086910","name":{"text":"ANORO ELLIPTA 62.5/25 MCGINH PWDR 1X30 DS","untrusted":true},"class":"B","nadac_per_unit":7.79597,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"66993013497","name":{"text":"UMEC and Vilanterol Ellipta 62.5/25mcg","untrusted":true},"class":"G","nadac_per_unit":4.94204,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":null},"generic_entry":[{"application":"NDA203975","date":"2030-11-29","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"11090294","productNo":"001"},"latest_patent_expiry":"2030-11-29","latest_exclusivity_expiry":"NOT_PROVIDED","dated_barriers":6,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":5,"exclusivities_listed":0,"fact_id":"1181a5f45406cfbc0119ffc7"}],"label_history":{"events_total":9,"non_cmc_events":7,"counts_by_class":{"LABELING":6,"EFFICACY":1},"cmc_events":2,"recent_non_cmc_events":[{"application":"NDA203975","submission_no":15,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2023-06-02","documents":[{"type":"Letter","date":"2023-06-05","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/203975Orig1s015ltr.pdf","untrusted":true}},{"type":"Label","date":"2023-06-05","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203975s015lbl.pdf","untrusted":true}}],"fact_id":"e0d28eb3300d973973c9c1a2"},{"application":"NDA203975","submission_no":13,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2022-10-20","documents":[{"type":"Letter","date":"2022-10-21","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/203975Orig1s013ltr.pdf","untrusted":true}},{"type":"Label","date":"2022-10-21","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203975s013lbl.pdf","untrusted":true}}],"fact_id":"e06022073586310a84fa9290"},{"application":"NDA203975","submission_no":10,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2019-06-06","documents":[{"type":"Label","date":"2019-06-25","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203975Orig1s010lbl.pdf","untrusted":true}},{"type":"Letter","date":"2019-06-26","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/203975Orig1s010_REPLACEMENTltr.pdf","untrusted":true}}],"fact_id":"169b7ca9b8dbaf5346d5783d"},{"application":"NDA203975","submission_no":9,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2019-05-29","documents":[{"type":"Label","date":"2019-05-30","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203975s009lbl.pdf","untrusted":true}},{"type":"Letter","date":"2019-06-04","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/203975Orig1s009ltr.pdf","untrusted":true}}],"fact_id":"2abf2db9a7b280f49ea724c8"},{"application":"NDA203975","submission_no":7,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2017-10-17","documents":[{"type":"Label","date":"2017-10-19","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203975s007lbl.pdf","untrusted":true}},{"type":"Letter","date":"2017-10-19","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/203975Orig1s007ltr.pdf","untrusted":true}}],"fact_id":"57f478817734b61bad95d083"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":1,"te_code_counts":{"NOT_PROVIDED":1},"marketing_status_counts":{"Prescription":1},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA203975","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"ANORO ELLIPTA","untrusted":true},"form":{"text":"POWDER;INHALATION","untrusted":true},"strength":{"text":"EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH","untrusted":true}}]},"recalls":{"recalls_total":1,"counts_by_class":{"Class III":1},"packages_of_these_applications":3,"most_recent":[{"recall_number":"D-0160-2024","classification":"Class III","status":"Terminated","report_date":"2024-01-03","recall_initiated":"2023-12-12","recalling_firm":{"text":"GlaxoSmithKline LLC","untrusted":true},"reason":{"text":"Failed Release Testing: Coarse Particle Mass for umeclidinium Out of Specification","untrusted":true},"packages_named":2,"fact_id":"d2b9b7219cb87e0b28b14364"}],"meaning":"FDA classifies the health hazard of a recall, not its effect on supply"},"spending":{"reported_under":{"generic":{"text":"Umeclidinium Brm/Vilanterol Tr","untrusted":true},"brand":{"text":"Anoro Ellipta","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":1002343776.1,"claims":1830197,"beneficiaries":375201,"average_spending_per_claim_usd":547.66988257,"fact_id":"d084a33581224f77594de0f7"},{"year":2021,"gross_spending_usd":912370401.83,"claims":1593170,"beneficiaries":338712,"average_spending_per_claim_usd":572.6761123,"fact_id":"84458c02deb8335ad5d1afd4"},{"year":2022,"gross_spending_usd":866849124.47,"claims":1439975,"beneficiaries":297142,"average_spending_per_claim_usd":601.98900986,"fact_id":"9f5535b555c865b53e7df32b"},{"year":2023,"gross_spending_usd":872959569.63,"claims":1390293,"beneficiaries":294512,"average_spending_per_claim_usd":627.89611228,"fact_id":"388571c4ee93384cb50711fb"},{"year":2024,"gross_spending_usd":819257997.62,"claims":1383988,"beneficiaries":291195,"average_spending_per_claim_usd":591.9545528,"fact_id":"968ec400d0bc1df01fa6fec7"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"medicaid_state_utilization":{"year":2025,"states_with_data":4,"all_states_medicaid_reimbursed_usd":50820.77,"all_states_medicaid_paid_prescriptions":532,"top_states":[{"state":"FL","medicaid_paid_prescriptions":153,"medicaid_reimbursed_usd":19552.5,"total_reimbursed_usd":19552.5,"packages":1,"covers":"fee_for_service_only","fact_id":"255331895a87479dc313ad72"},{"state":"IN","medicaid_paid_prescriptions":110,"medicaid_reimbursed_usd":12732.7,"total_reimbursed_usd":12732.7,"packages":1,"covers":"fee_for_service_only","fact_id":"ecdd12f22a67b362fa0ee964"},{"state":"TN","medicaid_paid_prescriptions":78,"medicaid_reimbursed_usd":11188.22,"total_reimbursed_usd":11228.72,"packages":1,"covers":"all_record_types","fact_id":"95f6e283c5575e525042b59a"},{"state":"KY","medicaid_paid_prescriptions":191,"medicaid_reimbursed_usd":7347.35,"total_reimbursed_usd":7347.35,"packages":1,"covers":"fee_for_service_only","fact_id":"575cbdfaf4936d7f300d5b91"}],"unlabelled_state_code_xx":null,"built_from_facts":4,"facts_fee_for_service_only":3,"older_year_facts_not_used":62,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"3fcbde65dfa49f214f7cf3a0","field":"ndc.listing","entity":"ndc:00173086906"},{"fact_id":"d0b292c2122dba845a8f00b3","field":"ndc.listing","entity":"ndc:00173086910"},{"fact_id":"01604119f1bf6f20bbd0355b","field":"ndc.listing","entity":"ndc:66993013497"},{"fact_id":"1181a5f45406cfbc0119ffc7","field":"drug.generic_entry_earliest","entity":"application:NDA203975"},{"fact_id":"27f6b69d8dc03b8f9a4c0e7d","field":"drug.patent","entity":"application:NDA203975"},{"fact_id":"e0d28eb3300d973973c9c1a2","field":"drug.label_event","entity":"application:NDA203975"},{"fact_id":"e06022073586310a84fa9290","field":"drug.label_event","entity":"application:NDA203975"},{"fact_id":"169b7ca9b8dbaf5346d5783d","field":"drug.label_event","entity":"application:NDA203975"},{"fact_id":"2abf2db9a7b280f49ea724c8","field":"drug.label_event","entity":"application:NDA203975"},{"fact_id":"57f478817734b61bad95d083","field":"drug.label_event","entity":"application:NDA203975"},{"fact_id":"55a5ccc2c1deea57020e6801","field":"drug.marketing_status","entity":"application:NDA203975"},{"fact_id":"d2b9b7219cb87e0b28b14364","field":"ndc.recall","entity":"ndc:00173086910"},{"fact_id":"d084a33581224f77594de0f7","field":"drug.partd_spending","entity":"drug:umeclidinium-brm-vilanterol-tr|anoro-ellipta"},{"fact_id":"84458c02deb8335ad5d1afd4","field":"drug.partd_spending","entity":"drug:umeclidinium-brm-vilanterol-tr|anoro-ellipta"},{"fact_id":"9f5535b555c865b53e7df32b","field":"drug.partd_spending","entity":"drug:umeclidinium-brm-vilanterol-tr|anoro-ellipta"},{"fact_id":"388571c4ee93384cb50711fb","field":"drug.partd_spending","entity":"drug:umeclidinium-brm-vilanterol-tr|anoro-ellipta"},{"fact_id":"968ec400d0bc1df01fa6fec7","field":"drug.partd_spending","entity":"drug:umeclidinium-brm-vilanterol-tr|anoro-ellipta"},{"fact_id":"255331895a87479dc313ad72","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00173086906:FL"},{"fact_id":"ecdd12f22a67b362fa0ee964","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00173086906:IN"},{"fact_id":"95f6e283c5575e525042b59a","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00173086906:TN"},{"fact_id":"575cbdfaf4936d7f300d5b91","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00173086906:KY"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price.ratio","reason":"no package has both a brand-class NADAC price and a negotiated price in force"},{"code":"NO_DATA","field":"supply","reason":"no FDA shortage row and no termination date for these packages"},{"code":"NO_DATA","field":"trials","reason":"no ClinicalTrials.gov record set for this drug's ingredient is in the edition"},{"code":"NO_DATA","field":"assistance_and_offers","reason":"no assistance program lists this drug and no manufacturer offer naming it is recorded; that does not mean none exists"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"orphan_designation","reason":"no FDA orphan designation for this drug's ingredient is in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}